Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 7.700-8.100 for the period, compared to the consensus EPS estimate of 7.600. The company issued revenue guidance of $28.2 billion-$28.6 billion, compared to the consensus revenue estimate of $28.4 billion.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GILD shares. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Thursday. Finally, Oppenheimer increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Price Performance

GILD opened at $103.31 on Thursday. The company has a market capitalization of $128.75 billion, a price-to-earnings ratio of 1,147.89, a PEG ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $104.71. The business’s fifty day simple moving average is $93.38 and its 200-day simple moving average is $87.24.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, equities research analysts anticipate that Gilead Sciences will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.06%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.